Selective estrogen receptor degrader

A selective estrogen receptor degrader or downregulator (SERD) is a type of drug which binds to the estrogen receptor (ER) and, in the process of doing so, causes the ER to be degraded and thus downregulated. They are used to treat estrogen receptor-sensitive or progesterone receptor-sensitive breast cancer, along with older classes of drugs like selective estrogen receptor modulators (SERMs) and aromatase inhibitors.

As of 2016 the only marketed SERD was fulvestrant ( brand name Faslodex). As of November 2016 other SERDs under development include brilanestrant and elacestrant. The clinical success of fulvestrant led to efforts to discover and develop a parallel drug class of selective androgen receptor degraders (SARDs).

Investigational
Fulvestrant requires large-volume and frequently painful intramuscular injections. In response, pharmaceutical companies are currently developing oral SERDs. Among products in development are:


 * Giredestrant: Roche
 * Amcenestrant (SAR439859): Sanofi
 * Camizestrant (AZD9833): AstraZeneca
 * Rintodestrant (G1T48) : G1 Therapeutics
 * LSZ102: Novartis
 * Imlunestrant (LY3484356): Eli Lilly
 * Elacestrant: Radius
 * ZN-c5: Zentalis
 * Taragarestrant (D-0502): Inventisbio
 * SHR9549: Jiangsu Hengrui
 * Vepdegestrant (ARV-471): Oral estrogen receptor PROTAC protein degrader for breast cancer by Arvinas.
 * ZB716 (Fulvestrant boronic acid).
 * Brilanestrant: Genentech
 * Etacstil: combined SERM and SERD
 * Palazestrant

The oral SERDs target ER-positive/HER2-negative breast cancer and are tested as monotherapy and in combination with other drugs such as the CDK inhibitor palbociclib (Ibrance).